Synthekine has issued the first dose of its STK-012 therapy designed to treat tumors. The open-label trial is in Phase Ia/Ib and is taking place across multiple centers.
In total, Synthekine is estimated to enroll 135 patients with advanced solid tumors. The STK-012 treatment works by selectively stimulating antigen-activated T cells, which are linked to anti-tumor activity and may aid in the stimulation of natural killer cells.
In preclinical stages, a mouse trial showed greater tumor regression in the STK-012 group than in the control, and the mouse surrogate’s toxicity model demonstrated good tolerability. These trials also demonstrated the absence of capillary leak syndrome, which is common in other comparable treatments.
Further, the treatment averted lymphopenia, demonstrated tolerability, and avoided capillary leak syndrome in non-human primate trials.
Synthekine CEO Debanjan Ray said in an interview with clinical trials arena: “STK-012 is the first programme from our broad portfolio of biased cytokines to enter the clinic, and its rapid progress into clinical investigation further highlights our team’s tremendous ability to execute efficiently and move our pipeline forward.”
Want to Learn More?
In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient perspective should be considered when designing studies to ensure that patient targets are met not only on time but also on budget.
For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real-time. The best part: these patients are already educated and prepared for the clinical trial process.